Adjuvant composition for vaccine as well as preparation method and application of adjuvant composition

The adjuvant combination of squalene, Tween 80, Polysorbate 188, and CpG1018 addresses the limitations of current vaccine adjuvants by enhancing immune responses and reducing toxicity, offering a safer and more effective solution for vaccine development.

CN119700955APending Publication Date: 2025-03-28ADVACCINE SUZHOU BIOPHARMACEUTICALS CO LTD
0 Cites 1 Cited by

Patent Information

Application Number
CN202411148380.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-09-28
Filing Date
2024-08-21
Publication Date
2025-03-28

AI Technical Summary

Technical Problem

Current vaccine adjuvants face challenges in achieving optimal immune responses while minimizing toxicity and side effects, with existing adjuvants like CFA/IFA being restricted due to safety concerns, necessitating the development of more effective and safer alternatives.

Method used

A vaccine adjuvant combination comprising squalene, Tween 80, Polysorbate 188, and CpG1018, formulated into a specific concentration range to enhance immune stimulation with reduced adverse reactions, involving a preparation method that includes emulsification and filtration to achieve a stable and effective adjuvant solution.

Benefits of technology

The adjuvant combination significantly enhances immune responses, reduces antigen dosage, and prolongs immune memory with low toxicity, demonstrating improved efficacy and safety compared to existing adjuvants.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, particularly relates to the field of immunology, and more particularly relates to an adjuvant composition for vaccines as well as a preparation method and application of the adjuvant composition. The adjuvant is prepared from squalene, Tween 80, poloxamer 188 and oligonucleotide CpG1018. Experiments show that the adjuvant disclosed by the invention is obviously superior to an adjuvant in the prior art, so that the adjuvant has an application prospect.
Need to check novelty before this filing date? Find Prior Art